SYGNIS will issue of up to 2,475,678 new shares against cash contribution at a subscription price of EUR 2.00, the Company expects to generate gross proceeds of up to EUR 4.95 million. SYGNIS plans to use the gross proceeds to finance its operating business, the development and commercialisation of its proprietary product portfolio.
SYGNIS is a German-Spanish stocklisted (Frankfurt) company devoted to the development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today. Demand for such tools is high in the fast-growing DNA and protein analysis markets. Read More
The world of medicine is shifting from the traditional “one size fits all” approach to […]
If the opportunity for the input of personal or business data (email addresses, name, addresses) is given, the input of these data by any visitor of these pages takes place voluntarily. The use of all offered services are permitted – if and so far technically possible and reasonable – without specification of any personal data or under specification of anonymized data or an alias. The use of postal addresses, phone or fax numbers and email addresses published on these pages for marketing purposes is prohibited; offenders sending unwanted spam messages will be punished.